A Phase II/III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Relaxin in Subjects With Acute Heart Failure.

Trial Profile

A Phase II/III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Relaxin in Subjects With Acute Heart Failure.

Completed
Phase of Trial: Phase II/III

Latest Information Update: 01 Aug 2017

At a glance

  • Drugs Serelaxin (Primary)
  • Indications Acute heart failure
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms Pre-RELAX-AHF; RELAX; RELAX-AHF
  • Sponsors Corthera; Novartis Pharma
  • Most Recent Events

    • 01 Aug 2017 Results of post hoc subgroup (n=1154; with or without substantial peripheral edema) analysis published in the American Heart Journal
    • 01 May 2017 Results of a post-hoc analysis assessing the impact of daytime versus night-time on baseline characteristics and clinical outcomes in patients with acute heart failure from Relax-AHF trial, published in the American Heart Journal.
    • 30 Jan 2017 Results of multi-time point-based multimarker analysis in a large well-characterized cohort of acute heart failure patients with significantly elevated natriuretic peptide levels and mild to moderate renal impairment published in the European Journal of Heart Failure.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top